Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...
Abstract: Objective: Current intrapartum fetal monitoring technology is unable to provide physicians with an objective metric of fetal well-being, leading to degraded patient outcomes and increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results